# Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)

> **NCT00310804** · PHASE3 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1200 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)
- **BIOLOGICAL:** Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)
- **BIOLOGICAL:** Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)
- **BIOLOGICAL:** Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)

## Key facts

- **NCT ID:** NCT00310804
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2005-10
- **Final completion:** 2006-04
- **Target enrollment:** 1200 (ACTUAL)
- **Last updated:** 2019-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310804, "Safety and Immunogenicity of 3 Lots of Cell-derived Subunit Influenza Vaccine as Compared to 1 Lot to Egg-derived Subunit Influenza Vaccine in Healthy Adults (>=18 to <=60)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00310804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*